- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Vlad Hogenhuis, Merck
S
Vlad Hogenhuis
General Manager for Neuroscience, Dermatology, and Ophthalmology, Merck
RECRUITED BY: Merck CEO Roy Vagelos
EXECS NEED: The courage to do what's right
I got a call from Dr. Vagelos, with the opportunity to be part of his mission" is how Vlad Hogenhuis, MD, introduces his 14-year career at Merck. Hogenhuis was getting a Wharton MBA at the time, but he has pharma in his blood. Born in the Netherlands to a long line of physicians—his father developed a migraine drug—he practiced medicine for four years before deciding to jump to industry.
Vlad Hogenhuis
He's climbed the Merck ladder by crossing from managing to managed care to licensing to R&D strategy. "I had a broad view early on," he says. Under CEO Dick Clark's new model integrating clinical and commercial, he directs both the late-stage pipeline and global marketing for a $1.7 billion three-disease franchise. "I have end-to-end accountability," he says. "There's full alignment of what the sales force does and what we do in marketing and even in Phase III."
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
